NPM1andFLT3andCEBPA Test Cost AED: 3900.0 – Symptoms, Diagnosis, and More
Welcome to DNA Labs UAE, a leading genetic lab in the UAE. In this blog post, we will discuss the NPM1andFLT3andCEBPA Test, its cost, symptoms, diagnosis, and more.
Test Details
The NPM1andFLT3andCEBPA Test is a genetic test that analyzes three specific genes associated with certain types of leukemia. The test components include an EDTA Vacutainer (2ml). The cost of the test is 3900.0 AED. The sample condition required is bone marrow or peripheral blood, which should be transported immediately. The report delivery time is 7-8 days. The method used for the test is Sanger Sequencing. The test type is genetics.
Doctor and Test Department
The NPM1andFLT3andCEBPA Test is typically ordered by a gynecologist. The test falls under the test department of genetics.
Pre Test Information
The NPM1andFLT3andCEBPA Test requires a doctor’s prescription. However, the prescription is not applicable for surgery and pregnancy cases or for people planning to travel abroad.
Understanding the Genes
NPM1, FLT3, and CEBPA are all genes associated with certain types of leukemia. Let’s take a closer look at each gene:
NPM1 (Nucleophosmin 1)
The NPM1 gene encodes a protein involved in various cellular processes, including cell growth and proliferation. Mutations in the NPM1 gene are commonly found in patients with acute myeloid leukemia (AML), particularly in those with a normal karyotype. NPM1 mutations are considered a favorable prognostic factor in AML, as patients with these mutations tend to have a better overall survival compared to those without the mutations.
FLT3 (FMS-like tyrosine kinase 3)
The FLT3 gene encodes a receptor tyrosine kinase involved in cell signaling and regulation of cell growth and differentiation. Mutations in the FLT3 gene are found in about 30% of patients with AML and are associated with a poor prognosis. The most common FLT3 mutation is an internal tandem duplication (ITD) in the juxtamembrane domain of the protein. FLT3-ITD mutations are associated with increased proliferation of leukemic cells and resistance to chemotherapy.
CEBPA (CCAAT/enhancer binding protein alpha)
The CEBPA gene encodes a transcription factor involved in the regulation of cell differentiation and proliferation. Mutations in the CEBPA gene are found in a subset of patients with AML, particularly those with a normal karyotype. CEBPA mutations are associated with a favorable prognosis in AML, as patients with these mutations tend to have a higher complete remission rate and longer overall survival compared to those without the mutations.
Prognosis
In summary, the presence of NPM1 mutations and CEBPA mutations in AML patients is generally associated with a better prognosis, while the presence of FLT3 mutations, particularly FLT3-ITD mutations, is associated with a poorer prognosis.
Thank you for reading our blog post on the NPM1andFLT3andCEBPA Test. If you have any further questions or would like to schedule a test, please contact DNA Labs UAE.
| Test Name | NPM1andFLT3andCEBPA Test |
|---|---|
| Components | EDTA Vacutainer (2ml) |
| Price | 3900.0 AED |
| Sample Condition | Bone marrow \/ Peripheral blood (Transport immediately) |
| Report Delivery | 7-8 days |
| Method | Sanger Sequencing |
| Test type | Genetics |
| Doctor | Gynecologist |
| Test Department: | |
| Pre Test Information | NPM1+FLT3+CEBPA can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
| Test Details |
NPM1, FLT3, and CEBPA are all genes that are associated with certain types of leukemia. NPM1 (Nucleophosmin 1) is a gene that encodes a protein involved in various cellular processes, including cell growth and proliferation. Mutations in the NPM1 gene are commonly found in patients with acute myeloid leukemia (AML), particularly in those with a normal karyotype. NPM1 mutations are considered a favorable prognostic factor in AML, as patients with these mutations tend to have a better overall survival compared to those without the mutations. FLT3 (FMS-like tyrosine kinase 3) is a gene that encodes a receptor tyrosine kinase involved in cell signaling and regulation of cell growth and differentiation. Mutations in the FLT3 gene are found in about 30% of patients with AML and are associated with a poor prognosis. The most common FLT3 mutation is an internal tandem duplication (ITD) in the juxtamembrane domain of the protein. FLT3-ITD mutations are associated with increased proliferation of leukemic cells and resistance to chemotherapy. CEBPA (CCAAT/enhancer binding protein alpha) is a gene that encodes a transcription factor involved in the regulation of cell differentiation and proliferation. Mutations in the CEBPA gene are found in a subset of patients with AML, particularly those with a normal karyotype. CEBPA mutations are associated with a favorable prognosis in AML, as patients with these mutations tend to have a higher complete remission rate and longer overall survival compared to those without the mutations. In summary, the presence of NPM1 mutations and CEBPA mutations in AML patients is generally associated with a better prognosis, while the presence of FLT3 mutations, particularly FLT3-ITD mutations, is associated with a poorer prognosis. |
